Earnings call transcript Q2 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to the Arcutis Biotherapeutics Second Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference call is being recorded.

to McIntyre, conference Head like speaker to now Eric today, of would hand over the your I Investor Relations. ahead. go Please

Eric McIntyre

Thank on the and everyone section of Arcutis call. Good for Investors for Cory. website. Slides available our earnings second thank are today our joining quarter you, you afternoon,

Frank today, Burrows, Chief CEO; Medical and President Scott Ayisha Officer; Jeter, the call Watanabe, Commercial Burnett, On our Financial Patrick Officer. Chief we have and Interim Chief Officer

during we and in I'd to These be differ will this remind statements certain uncertainties, call. information our are forward-looking and materially. that filings. actual to subject disclosed everyone SEC review the you statements making may latest We risks encourage results

intro, the With I'll Frank. call hand to that over

Frank Watanabe

brief it I'll introductory comments Thanks, And Eric. and over the some turn experts here. I'm going make to then to

launch I'm is build So our leading company. that slide slide strategy the for fronts to sustained our ZORYVE growth. of strengthening on really dermatology the long-term deck. proud I'm laying solid X is effectively innovation-driven on foundation on all executing team The

we've current of we're opportunity even around which And size TRxs building QX, feedback positive still Physician is in just QX is the real-world launch on clinicians the by We're with far growth really and positive versus encouraged experience ZORYVE. broader and market. patient remember, remains seen the steroid our topical further saw XX gain in exceedingly scratching we And script and XX% momentum. here QX. so growth the growth the as surface nonsteroid roughly times in

we're to July. in is our coverage CVS long-term the broad have high-quality steroids announced element early success access topical One the broad the key to from and unlocking in thrilled obtaining and decision conversion

unusually national launch, million we've is authorization, any XXX In less access. at health those have for large we to more goals pricing all without strategy. think high-quality as secured now our access three any as XX% our is meets access XX and commercially plans and validation well other which the ZORYVE downstream prior fast insured and launch of which months large Currently, PBMs than coverage access of than of have for from over patients patients

to the as net previously gross to pleased second also report quarter in indicated. we improved has I'm had that

QX. so execution net expanded expect in to seeing improvement we with QX being QX in And far our gross additional as improvement part highs all-time we focused covered of in percentage to improvement as in are and the due well coverage the reaching scripts and further additional

launched to In US for we're from US. executing Beyond patients excellent and reception and the an access future. the the ZORYVE we've high-quality June, same the achieved Canada building build thus in also that rapid as we've progress physicians in well launch, we ZORYVE far as in had

and days, script three early representing still top half It's healthy been growth more market. already but has payers private secured ZORYVE we've of coverage for the Canadian private the the than with

of and foam protection delighted a new U.S. of the our overall We covering for protection which we're seborrheic extends dermatitis seborrheic dermatitis and that's cream XXXX, and roflumilast IP foam treatment with obviously patent recent with of also patent the patent a new already top strengthened of patent XXXX issuance strong We very enjoyed through methods and the on estate the roflumilast by through this foam with. way.

seb ZORYVE quarters molecule very but every reminder it's in patients ahead. roflumilast body in makes good then of products in multiple we and to US this derm today, quarters slide previously, a XXXX. of slide for four as potential psoriasis think a We've potentially dermatology beginning offices. now upcoming at and unique I the about market it in possibly launches with the launches in in also and execute competing psoriasis have XX the treated second of Then topical true half to their we're opportunity X scalp turning one with a six. what million for of So three two shown the With we

have the dermatology in expected and which large of office, of very care dermatitis, primary are treated approvals opportunity also particularly We outside the frequently the a in both seborrheic dermatitis with atopic setting.

cost-effective care indicated but force, partnership us this intend to our do in help way. a have not we build As we look market sales for before, to we'll own a access primary

current those competing that's the So XX inside opportunities when both six-fold and dermatology market increase than all million a a we're pursuing, addressable we're in. and more you factor out, psoriasis patient over in market

Now, the few want details her Officer done CCO, she's Jeter, to But And And want to well you I impressed in on the Commercial we in performance I've on see our do, with Ayisha's Chief I Commercial to we as her Chief performance. launch. Interim Interim Interim is leadership. She for when past permanent months. our turn ZORYVE comment fill strong more that to providing commercial Ayisha can I call been not team as has the while beat ability appointed a before about an incredibly to a our search to doubt have recent how CCO Officer. our filling sales in role. over missed no over as provide I

And Ayisha that ahead. with go

Ayisha Jeter

Thanks, Frank.

eight. performance slide Moving on to commercial

the profile across dividends payers. pay and starts of Everything of patients’, with aspects core, growing continues all the launch. proud at are to our strong physicians We ZORYVE's which with momentum product

of more and the We clinicians their perform as world can are real in steady prescription determine a how ZORYVE seeing gain growth patients. experience for variety

companies successfully to adjust doing just past, needed is evaluate and team the our need that. to in said launch and as constantly tactics drugs we've As

ways ongoing and look further we forward. adjustments improvements and will Our reflect to in our results going for optimize performance QX our

this demand On slide, IQVIA we're data. showing

and July healthy QX, post quarter TRx one TRx XX% in in further both NRx all-time growth approaching Xth quarter-over-quarter we surpassing highs into in Now, of to consistent growth with the trends year see growth launch, plus the nearly third date, holiday.

especially as in intertriginous the exceptional, with and once-daily in remains ability on anywhere that efficacy the sensitive it patient use on the in treating of well elbows clinicians ZORYVE's as its be profile body, on and HCP course, in of treatment areas, areas the to can most the very rapid as and used And the difficult plaques really patients feedback and real favorable positive its tolerability knees. well. like ZORYVE world performance feedback appreciate effectiveness

and have that slide to we net ZORYVE Since Moving to patient launch, access improvement. gross nine. for unblocking broad drive in great high-quality made demand will further strides

on commercial insured ZORYVE. patients PBMs easy how obtain of ZORYVE their largest mentioned, Frank is which mind HCP's is for now to commercially gives about top As peace the covered formularies, their national three on it

think million have in where of or access this XXX the we covered, lives don't over be for commercial now HCPs With not With may XX% reimbursed. may have to US. secured coverage, ZORYVE commercial about broad lives

Importantly, which of paper. authorization, that pen prescribers reduces our limits topical of typically believe facilitating a profile to XX% from long-term We is to with prior household over steroid. conversion the critical factor product commercial from along this that lives are covered the XX% without putting distinction

XXXX. We dermatitis also launches enjoyed coverage in expect help our dermatitis that the atopic also high seborrheic will in with by and quality expected ZORYVE

best recent formularies in high-quality On label of differentiated Slide psoriasis notch favorably clinical for these is commercial coverage profile national a being details sensitive or slide and the XX areas, for the to responding on our broad with are certainly not patients example our PBMs. ZORYVE's with the most CVS Payers with the three what largest in requiring aligned step for patients a practice. ZORYVE

have time where a certainly pricing we compares number evidenced our as favorably Our an launched advantage preferential is topical criteria coverage and management to by resonating strategy of to growing tier access recently and branded instances with other in utilization payers agents. status

sensitive with recently areas. clinical of to step a population. ZORYVE there where also valuing Like to see the to non-steroidal. the guidelines, making therapy requirement branded outside to coverage And also its another imposed payers patients other step the with just VA is requirement new for clinical updated commercially the through VA progress CVS, no of step We're example in -- get plaques insured profile we ZORYVE. of The

steroid coverage ZORYVE over ultimately burdensome long-term. makes As we along, write, for less differentiated topical health high which critical this providers care the market said all to converting is to the quality

benefits our also gross net. starting of see on and improved coverage Additionally, to field focused our execution to we're

field Our on board. fully is now team reimbursement

further have making sales And is co-pay offerings. our team our strides prescriptions. We fine-tuned positive through covered pulling in

and in and right tactics against are place plan have the executing that. We

saw in improvement In QX, that covered accelerated we improvement the of and percentage prescriptions QX. in has

giving In our July, in us confidence in of month seen team's plans prescriptions covered our execution. in and yet fact, terms best we've

the across prescriptions are July, percentage the we improvement in more the than reimbursed of in all coverage have doubling a seen major Most We in of covered early decision since CVS. seeing by percentage notably CVS prescriptions PBMs.

in our with that net sales coupled QX gross coverage to our which QX, in produce conviction reinforces gross target further steady-state We with time. execution expect improved achieve can improved our over improvement net force to to we

Slide remind all we've set to I pillars out commercial On success three ZORYVE XX, that of will for the growth. sustained you

awareness First, driving base. expanding the prescriber HCP and

over prescribing our the launch. unique highest frequency since focused seen X,XXX now reach writers and remain have We increasing We on providers. health with care

further to begin time, of actively a have providers same of HCPs there yet headroom we're non-steroidals. for and prescribing newer the targeting lot expansion is those At still who the

were XX%. of the of QX in patient growing QX Second month in indicator potential long-term for important an XX%. Sustained ZORYVE, approximately is ZORYVE. patient of also increased refills the we July, It Refills are averaged engagement and and very -- growth to In XX%. nicely. is to to here adherence our experience. approximately QX encouraging And achieve

as ZORYVE to dermatologist that In we a we the a which TV XXXX progress And to time our said, patients is the long-term we We the board focused the launch leg ZORYVE. of access to forward next fuel delivering on ZORYVE. more previously look promise on at on result, With efforts this connected look live going right our into later enhancing of beyond. as ask will with feel for and comes campaign DTC would will their quarter, broadly. be coverage, activate we recent closing,

I hand Patrick. it to over And will with that,

Patrick Burnett

a mentioned From these on wanted on as building are on our milestones. track, Slide earlier. Thank sustained you, Frank long-term regulatory And clinical to Ayisha. all near-term my I remain just provide XX. update end, and growth These quick potential significant

off derm. with starting atopic So

five-year-old AD on INTEGUMENT-PED is And the later two this population. a - the as readout to have this for reminder, study We in quarter. track

in dermatitis X the also sNDA Xand submitting forward atopic positive the based above We for look late QX, readouts. and QX ages early six to INTEGUMENT- on for

lot December dermatitis, already in disease Turning have field. the for a the set and to our is excitement we And doing right HCP team state of medical seborrheic high. PDUFA we're now, XX with awareness incredibly

we adolescents for the in the age this approval the adults quarter. that now unique to psoriasis. with We'll for down additional first look areata, early on potential our started We healthy our existing share nears two, a for study, psoriasis. have on to enrollment that Xb in label for topical And completion. we've forward of ZORYVE this fourth enrollment progressed pipeline. it on Briefly JAK and and study of to our study. expansion update label on a to areata Phase in the alopecia in one more subject initially as volunteers alopecia Recall And builds

that, I'll With turn Scott. it to over

Scott Burrows

Patrick. Thanks,

pleased of meaningfully call well Recall, were to as deck. growth we improvements to driven the as quarter-over-quarter of most Page quarter communicated the in earnings be in growth driven we quarter. net. by as by are $X.X $X.X would our million revenue XX, our expected second growth well to Turning QX. were revenues in second to but gross demand, nearly Net see revenues Total contributing XX% million improved product gross-to-net that slide we demand last

recognized other ensure as coverage as prescriptions Ayisha and expanded Based In highlighted, previous expect second the efforts revenues, was in QX in which insurance received QX. collaboration we improvement are to the in processed further we covered that quarter, an also stake to as gross well from appropriately improvement of on the equity a continued value prescriptions, our net $XXX,XXX partner.

costs, as rest development second our decrease due were quarter. to is million clinical in Turning expenses to the we $XX The wind of year-over-year the down and Research roflumilast programs. development topical lower P&L. the primarily

quarter, roflumilast reduce versus in comparison favorable quarter first the and broader FDA $X In cost, onetime efforts from benefited early-stage programs. true-ups filing our some R&D dermatitis development first our lower the to study also fee the million spend clinical to seborrheic addition the in

from study up For million we expect same back tick as do QX, closer R&D expect the to we favorability to not $XX onetime would true-ups.

We R&D XXXX. expect down in further step a in expenses

were $XX and in million ZORYVE in SG&A our launch quarter, for continued the expenses the and upcoming the reflecting dermatitis. separate atopic investment dermatitis launches

to and quarter same begin Net compared the $X.XX QX, for SG&A last into focused in year. will later expense the efforts loss mentioned, over TV share our Ayisha quarter we connected As driving this per $X.XX some growth. was additional

on cash balance items. of our to million Turning XX. well flow page remain final of and XX, key provide We as $XXX cash some slide sheet we June capitalized with

second Our by payments. certain burn of lower timing driven decreased in R&D the quarter, the and costs

Similar the cash grow a back expect derm Over to time, psoriasis my burn trend operating seb indications. in comments, to downward general would quarter launches. in we multiple we'd expense the benefit sales continue across up quarterly burn cash we slightly invest as revenues upcoming expect we third from and in to as as and tick

sheet strengthen efforts. also confident ex-US This further We remain with the capital update. to e-licensing the concludes ability financial balance non-dilutive our near-term through in our

the now I'll Frank. to turn call back

Frank Watanabe

Scott. Thanks,

team. thank the like would I Arcutis all, members of first the closing, in just to of So all

these are of the for our taking to impressed out our day want to and of team. earnings call. also As you folks I imagine, to incredibly am I everyone of thank hard dedication call the quarterly constantly can your deliver results, on working in by time you

And that, questions-and-answers. we open wrap-up things will and up with to

Operator

you. Thank

Van session. a from question-and-answer Instructions] first comes TD Tyler Cowen. We Our of [Operator Buren will now conduct question

is Your open. line

Tyler Van Buren

Hey, occurred of percent afternoon. are coverage great It's an improvement and see the that cover at guys, to prescriptions you the And the quarter. last good high. in all-time mentioned, over

May a But QX gross on June as the question during cadence of net but online percent gross to into the percent question, of additional the I presume improved prescriptions of related, for the then think about Can of detail what net talk QX relative just quarter. kind you as So is, separately trajectory PBM May was than first we QX? better the to were is improvement to And April which was relative July and during heading and significantly about came the -- what and during for covered June X. QX? to the second May? on -- second

Frank Watanabe

little Tyler I'll I'll for your Maybe into take then detail your Ayisha the on more So, one questions. thanks and go question. first second to

of that that every percentage will but detail into upwards seeing really a that's talk do quarter in the prescriptions And that covered. end we steady improvement. percentage as are aren't terms the In comfortable we want in I improvement? quarter of to we mentioned getting covered say probably a level a about within includes since what of QX I further you of saw of Ayisha, cadence earlier we've the maybe seen trend terms

Ayisha Jeter

Sure.

relates what off, we the did deductible as then first different -- implementation their field of PBM see a that got there as then deductible coming reimbursement two the improvement note was saw would it the number improvements relates thereafter further was We to place team. actually in related board to Secondly once improvement and on One So started we with to to I an is that there through resets. some components. it patients see to as couple was start pull-through

Eric McIntyre

can the to next we Cory think question. I go

Ayisha Jeter

Cory. ahead Go

Frank Watanabe

Cory, go ahead.

Operator

Yeah.

Morgan Purohit question next of comes from Stanley. Our Vikram

Vikram Purohit

for questions. both ZORYVE We two our on Thanks taking psoriasis. and afternoon. good had Hi,

could of time you changing net then in the mix First, do what's getting gross just bit line back Thanks. terms step line of prior ZORYVE thinking back think like what And net over taking color current you of prescribed on might to could look provide patients use, since to a steady-state on but launch for what secondly, And your gross a there? treatment the being that? to a your like? is things status be time how of

Frank Watanabe

Yeah.

about I'll maybe Ayisha then I'll mix take patients. the and talk of one ask So second to

But we a confident that that remain ability to XX% to and we our continued we've get in in that we're net And improvement say QX. state to to will seeing I the to perfect. that the data believe with our range. I gross somewhere in say think in particularly today Although in steady QX isn't granularity in still XX%

bit take certainly, we than to initially reach. well it's I But longer a that's little us within we anticipated. think probably going get there to had think what our

and that somewhat think time unusual state think in to steady launching seb We're I with early window get is to the same has that I sometime in multiple before impact XXXX. in circumstance AD XXXX predict. in product timing then scalp mid-XXXX new exact a expected to we time every XXXX and in launch early we're in The a of derm you gross then difficult on your And trends. really net the products launch

going point, say at going forward it point us be So in I and said mix call we'll to when as I this think to we get at don't get Ayisha, also that. too but seeing. But more will early it's we for before, won't of it's it's think to we're difficult update this steady I to certainly XXXX. maybe about you XXXX, a can that exactly state. talk I patients the guys on think you be clarity

Ayisha Jeter

Absolutely.

Vikram So relates patients. to it as the

first what the discussed in past. it's we've similar So off, to

that and/or it's have steroid it's mix then patients single most other First, tried been steroid topicals. a And the the a part. for have patients tried a that of also

Frank Watanabe

of Can psoriasis every I continuing patients. into a add year, Great. year. of new In system given amount patients as There's not huge XX% the just just patients any reminder. a coming are

have on plaque patients previously something the for most so been And psoriasis.

Vikram Purohit

you. Thank Understood. Sure.

Operator

Thank you.

Guggenheim Securities. next comes Our Fernandez question from Seamus of

line is Your open.

Seamus Fernandez

for Thanks Great. question. the

that us time? a in So of get point quick currently just trying questions. you and are of number to this understand marketing two accounts the in Can sense at better guys you help to Just that.

use. that and growth practice internal practices of But in like deliver, shown done strong would and of among pretty for really of work is growth with there kind Some both kind ZORYVE lot the that penetration physicians growth you're promoting a growth it has of users greater additional Vitama growth script and that that that's to if their drive the for survey experience going actually of the expectations to it that we've good ZORYVE. seems isn't

then efforts And fully to approved? launch help can us with sales just separate marketing you is indication the and the force believe current the -- Thanks. the to incremental you're resourced foam Derm is understand launched whether that, you once Seb and

Frank Watanabe

physician you're you when accounts, accounts, about Seamus, talking say Sure. right?

Seamus Fernandez

Exactly. yeah. Yeah, Correct.

Frank Watanabe

Yeah.

X,XXX So that and prescribed now, Ayisha ZORYVE, about about on XX,XXX of that's have physicians right targets. call think mentioned I the unique out

to of on bringing headroom quite still terms prescribing a in there's So doctors bit ZORYVE. new of

And and the still size if reference the market, size deal steroid about great a base the even there's started in markets, made adopt to the then non-serial think XX I I prescribing today of deepening times the topical of those of to think this, well. you facet, other market as of being in in ZORYVE, those that offices upside have the terms

think we those, of well prescribing base. growth as both the an So expansion about of base of both the being deepening as as the

mentioned, think, scratching introductory the I from just the And my steroids built in dermatology momentum as, we I the the surface in I around really away move as think, think community. we're particularly that think, comments, I

your I'll again Derm Seb regard ask Ayisha for CCO. launch with maybe then on And same resourcing as question around to to that comment

Ayisha Jeter

Absolutely Frank.

relates education but it as more on disease providers doing not well-resourced is to awareness focused patients. hyper-focused the So from ensuring to team as the more a just force importantly providers perspective. Right now well the marketing is state we're as the it and resourcing that to sales on

resources our accelerate very to launch we -- confident the Seborrheic -- feel not right that Dermatitis. approvals to me have help excuse approvals, definitely our us currently So for in now

Seamus Fernandez

Great. Thanks for the questions.

Operator

One question. you. next moment for our Thank

from of question Uy next comes Mizuho. Our Ear

open. is line Your

Uy Ear

question. my guys, for Hey, taking thanks

think seeing number, it probably something. if one. don't continuing early, you Like X% of, Just patient you lot mentioned, use know -- the the to patients off but not? or But going speak is you, you rate? persistent what or are more I a a quick are refills can to also Could therapy I sort it's the too

terms XXXX a you Could financially, going you think, And in Thank downtick. to you're see spend? of second question that you. the I quantify in guess help mentioned Scott that us R&D I

Frank Watanabe

Yeah. okay. Yeah,

early mentioned have of grown So to that in ZORYVE, gauge refills exactly of still that July days terms total think XX% what very is. in now I Ayisha on it's volume. persistence, persistence to

so steadily increasing And a have we certainly of seen from number patients. refills

frequently. patients some are refilling quite are There who

that refill the at I as tail patients think But as seen times. previously mentioned the think the five Ken really of I skinny we've that's bell-shaped end many curve.

something that tubes think We year. is continue like three to a probably

be of refill up the prescription And bulk their that just so on patients that's right something coming to continue first now we'll may but monitor.

the rarely with to of from trial shared ever think side due hear we've I clinicians where due a one past efficacy In continue is tolerability XX% they if improved that's things that of in and really terms see effects non-response of on ZORYVE, very our think the we data that consistent or to I encouraging in to the of which discontinuation ZORYVE. lack is patients clinical to

in least effect our XX% been hear if And the trials. adherences than in saw label. the recall, has we the topical not good better as our you side about anecdotally again long-term is study extension we case historically that profile And what study at higher in what long-term what's it's in than probably

the are Uy's definitely the encouraged around then Scott, question we can early maybe signs you take expenses? And adherence. around So by

Scott Burrows

Hi Yeah. Yeah. Uy.

the have ZORYVE study to and key drivers will That a we still on spend in long-term it's XXXX. reduce would but for get spend our R&D too our specific bit again So AD ongoing. early study be say, I'd extension pediatric

R&D in efforts we're the some our line. until to derm like seb And continue of manufacturing hit example approved ongoing for

out that approved, line. that's the R&D once So will come of

And the drivers are key going XXXX. into kind so expect that's -- those we'd of that

Uy Ear

you. Thank Okay.

Operator

Thank you. One our for moment caller. next

the line Goldman Shibutani of comes next at question Sachs. Chris Our from

line Your open. is

Unidentified Analyst

detailed And the the are to see that share in -- they gaining this help the you extent ZORYVE Hey point? prescribed who team. characterize for think This they yet Stephen of for have from question. Thanks value physicians? group us, either that not to among and how is Two on physicians you been versus us haven't adequately the my mind product taking don't can Chris. about they

can now ads. why the is just marketing then do think TV talk And you is, to right second time you question about our

had I think payer you previously coverage. a of until level sufficient you about you talked felt had

there. make would hear want Thank that to thoughts you. So sense. your But just I

Frank Watanabe

sir, you those maybe Yes Ayisha, can take two?

Ayisha Jeter

Absolutely. Yeah.

I So we this have is first yet do to using to I as prescribers it topical write have have that yet recognize habits the ZORYVE, -- do are ingrained with providers those at there relates that to prescribers think think that is are steroids.

our because helping when going is the bought understand them utilized proposition ZORYVE to in ZORYVE the and as team profile. and importance, is absolutely talking are have a of and So them we on have the consistently what to reminding value of reminder in that there those you're that prescribers love clinical out

Now, been question the And ZORYVE it wait turn we've our this to correct, it fact for go flip quite you switch for and but some and secondly, on that coverage be your mass to as and the on. great time, that tactic are feel we that where place. we now at relates DTC, ahead to in are we evaluating to wanted critical

Unidentified Analyst

Thank Perfect. you much. very

Operator

question. next Thank you. our One for moment

from Our next Cantor. question Chen of comes Louise

Your line is now open.

Louise Chen

Hi. Thank my you question. for taking

you you here? So did psoriasis build greenfield the wanted on payer for any ZORYVE that you your to could seb confidence a for derm I what atopic work you you gives opportunity? in opportunity derm leverage of Secondly, ask can

this for more year and be What ideal we next lastly, when an year do a Thank likely you any primary company you. how And of then, partner? And would it timing thoughts be on about might beyond? care see something you? would think

Frank Watanabe

Sure.

to to a PCP So, derm Ayisha seb little the bit excuse as then coverage I'll clinician. going about I'm about around piece, going Patrick think I'm sure to seb Ayisha our then talk ask the to then and derm, is and him I'll that around -- sorry, I thoughts we'll talk And me, ask piece. about asleep make a ask not talk to address and

of we second to with the in consistently, benefit think year. really probably want is which we PCP around we partnership, like that it to be launch, have is timing saying Just next standpoint a a place could I feel atopic that to something dermatitis half the have doing been earlier. There from regard

in seb derm we as we setting think for get will derm. seb to It as momentum like rush didn't I But going. ready the get often treated care Again, is primary to the had feel partnership we well. contribute

probably So second frame. next would to half I something year the is likely yes, of look time most

capable calling And care terms World, and partner, GPs very force with who and internists the lot as large on IDeA a of primary well IDeA the of care are in then as dermatitis both, sales primary a physicians [ph] seeing an patients. it's company a in pediatricians atopic

there less I think is be just opportunities. little of would in but the that too mix And if of that bit great allergists of three sheer critical that's size a because the relative the --

someone for think having works us good I and execution who the who's our is well thing very most important someone at with team.

do an opportunity And building we much talk then into stepping Patrick, existing really and derm can to just seb need you versus maybe a the little about how bit market.

Patrick Burnett

absolutely. Yes,

it's that's started key patients dermatitis just and as about borne many psoriasis. in office. more in. been to seborrheic when already one office things out of dermatologists' they're is by think dermatitis And early I repeated They patients people talking we conversations. And that seborrheic heard this do we the And very in and their more they just have just as ad boards come them.

Keep drug decades. that hasn't in new mind there for dermatitis for seborrheic a been

of And kind be their be that to bringing for the to able is patients. HCPs a really something as non-steroidal to first new so offer to now opportunity we're treatment going them

And some antifungals gets these really dermatitis them when And with been practice, don't using have entirety treated steroids patient already. they've their they them. they've now of anything the a in seborrheic and with offer most topical referred to For combination. to of oftentimes been

the with seeing of rewarding. that's excitement this give just being of be have going they're over HCP reasons treat think that them. something to able now very a fits new to I it's we launch physician think the that patients one things it And really one is, makes high because mentioned So to I that and I them already that's

with practice. it so, fits really And nicely think the current I

Frank Watanabe

little a about psoriasis And and then bit coverage, Ayisha, interact? want talk do derm seb might to and how you

Ayisha Jeter

absolutely. Yes,

certain we seborrheic agreements build So our done actually payer in to place. access I agreements what alluded to help with dermatitis. know past going foundation built date having for psoriasis is with we the with have the groundwork us to already that's we've key in the that to

order so able going to -- for seborrheic to provide dermatitis. that access in the what's us foundation the secure we is And access with be that the need to

Louise Chen

you. Thank

Operator

One you. our Thank call. for moment next

call next Sean of comes Kim Our from JonesTrading.

is line open. Your

Sean Kim

one taking follow-up for my just question the base. I guess questions. you Thank Hi. on prescriber

you the X,XXX And that of in if of per how just any how high you prescribers? the prescriber. prescribers seeing many are of for are in call, X,XXX areata. all prescriptions that earlier And And number also on improvements one high pipeline is considered terms considered mentioned question alopecia mentioned, that you're the dermatologists prescribers? So many unique of

top any the there are if timing what wondering Just of efficacy that endpoints and readout line you. for program? might Thank be

Frank Watanabe

Sure.

and base, Dos, I in nurse So it's with relative think as clinicians dermatology to working that's XX,XXX are practitioners a regard physicians' MDs, There well assistants. prescriber term. as around probably

higher XX,XXX then obviously as are gradations the we're clinicians. And prescribing already there the that targeting So well. are within that

XX got lower decile it. you very decile the high small prescribing a can physician you've the prescribers, the the then and think There's right number. X, a relatively highest group X, doctors. of doctors about volume so-called That's prescribers small clinician And or of relatively if then middling end decile

between to likeliness newer Ayisha mentioned,. and use the no volume. I And there's nonsteroidals think correlation as

You who aren't the using doctors nonsteroidals. very large volume new have some

volume relatively low low very some who are. doctors have volume or You doctors

well. to of – have volume doctors you fortunately are newer total at looking then their of ZORYVE the nonsteroidals writing high-volume add as you it any really But wanted including back prescribing the if I lot the relevant that a basket have who you don't right entirety it basket. just comes additional the And Ayisha, prescription across characterization prescriber of the comments the know to about base.

Ayisha Jeter

Frank. else Nothing

I think you've covered it.

Frank Watanabe

can I little about And maybe then you Patrick study? the a Phase bit talk

Patrick Burnett

Yes, absolutely.

this yes Phase So a Ib trial. is

next alopecia certain expectations us the We're volunteer to our Phase not at So patients portion it's that trial safety data, a we're well as looking give use clear We've right completed efficacy. inform the mentioned. efficacy as a tolerability designed enrolling I and profile, areata to trial. really potentially II healthy really PK as biomarkers we would now within on read

right into be study, with to to what that regard where anything more on that little With back give of clearer of enrollment line of not idea are as a we'll further just the have we bit But I come about to it. time ready as we that. information get and you in timing we will a the exactly we're now, think study more the given

Sean Kim

you. thank Yes,

Operator

you. Thank

Next of Bhasin from question Rohit comes Needham.

is line Your open.

Rohit Bhasin

trials? upcoming talk on expect about Rohit III Phase in is Should the are different of this previous than coverage care Serge. trial? where you currently And just Can we be you expectations where for and terms what then you INTEGUMENT-PED the stand Thanks. to managed Hi, results for your line? down expect

Frank Watanabe

address Sure. then Ayisha can maybe the INTEGUMENT-PED? you Patrick about question managed talked care

Ayisha Jeter

Sure.

for coverage me. have So, of to XX% our our have coverage first our is care commercial I of there the earlier of to off, XX% ZORYVE then we psoriasis in as plaque XX% excuse for not managed those relates to commercial authorization. do for no remarks, And it prior as patients it relates patients as noted

receive Additionally, of patient I commercial outside notice say did that ZORYVE. for will we receive VA we the from the did is access population

so for with that plaques guidelines there have no areas. that sensitive in have updated is been where clinical And step the sensitive ZORYVE patients required have

Patrick Burnett

up can I pick INTEGUMENT-PED. And Yes. on

the both reminder in and those just trial. in X.XX% dermatitis similar it's efficacy were So II a two X.XX% a study a that with and studies that olds between to doses in and the two looked the dose X.XX% atopic the as Phase is with five-year the

for and and the profile what in safety of at atopic we development readout two INTEGUMENT with showed six above. program. earlier that dermatitis efficacy very and efficacy would different ranges our is And to similar In one when see similar ages INTEGUMENT-PED tends the have looking across we clinical to age a expectation general,

Rohit Bhasin

you. Thank

Operator

to time, Thank the I CEO. you. At to Frank this now Watanabe, would like turn conference back

Frank Watanabe

and for everyone calling in for group you really Well, again a Okay. all, good of thank first questions. as to once thanks of usual

analysts And lot. again next look to days quarterly a for the I company. that group are in talking call. a wonderful to we the Thanks about blessed think we're of with forward covering XX everyone

Operator

you participation. concludes This Thank Thank for call. conference today's your you.

disconnect. You may now

Arcutis Biotherapeutics (ARQT) 8 Aug 232023 Q2 Earnings call transcript